Divi's Laboratories quarterly results and financials

Divi's Laboratories (DIVISLAB)₹11,566+4.22%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Divi's Laboratories reported sales of ₹3,069 Cr, up 27.8% from Jun 2025, and net profit of ₹900 Cr, up 65.4% year on year. For the year to Mar 2026, sales were ₹10,535 Cr and net profit ₹2,565 Cr.

Sales (Jun 2026): ₹3,069 Cr
Net profit (Jun 2026): ₹900 Cr
Sales (FY Mar 2026): ₹10,535 Cr
Net profit (FY Mar 2026): ₹2,565 Cr
EPS (Jun 2026): ₹34.06
Borrowings (Mar 2026): ₹6.98 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Divi's Laboratories quarterly results

₹ crore unless stated; each column is a quarter.

Divi's Laboratories Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,904	1,849	2,295	2,110	2,329	2,312	2,575	2,401	2,706	2,598	2,824	3,069
Expenses	1,426	1,361	1,566	1,491	1,616	1,571	1,694	1,676	1,821	1,709	1,889	1,819
Operating Profit	481	491	733	624	718	746	888	731	891	893	937	1,260
OPM %	24.9%	25.9%	32.0%	29.0%	31.0%	32.0%	34.0%	30.0%	33.0%	33.9%	33.0%	41.0%
Other Income	86.21	95.24	79.18	79.22	106	82.13	86.16	119	145	14.03	155	64.11
Interest	1.01	0.00	1.99	0.00	1.01	0.00	0.99	3.01	7.99	6.01	5.99	6.01
Depreciation	94.92	94.88	94.94	96.90	98.96	98.89	107	112	113	118	120	133
Profit before tax	469	489	713	604	722	726	865	734	913	781	964	1,180
Tax %	26.1%	27.0%	25.0%	29.0%	29.1%	19.0%	23.1%	26.0%	24.1%	25.0%	22.0%	24.0%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−54.19	0.00	0.00
Net Profit	347	358	537	429	509	588	661	544	688	582	750	900
EPS (Rs)	13.14	13.53	20.32	16.24	19.25	22.25	25.02	20.57	26.01	22.03	28.38	34.06

Divi's Laboratories profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Divi's Laboratories Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,764	4,050	3,878	4,927	5,378	6,949	8,937	7,743	7,819	9,325	10,535	11,197
Expenses	2,345	2,604	2,613	3,062	3,553	4,091	5,053	5,380	5,612	6,368	7,088	7,239
Operating Profit	1,427	1,454	1,274	1,880	1,831	2,877	3,894	2,376	2,217	2,981	3,451	3,980
OPM %	38.0%	36.0%	32.9%	37.9%	34.0%	41.0%	43.0%	30.9%	28.0%	32.0%	33.0%	35.6%
Other Income	93.20	72.16	107	154	186	57.13	112	345	336	349	434	379
Interest	4.99	3.01	2.01	4.99	7.01	2.01	1.99	2.01	3.99	2.99	23.99	26.00
Depreciation	118	123	142	169	186	256	312	343	378	401	462	484
Profit before tax	1,392	1,395	1,232	1,855	1,820	2,665	3,686	2,371	2,163	2,918	3,391	3,837
Tax %	19.0%	24.1%	29.0%	27.0%	24.1%	26.1%	20.1%	23.1%	26.0%	25.1%	24.0%	—
Exceptional items	−3.01	−1.01	−4.01	0.00	41.19	−2.01	−2.01	−1.01	−3.01	0.00	−55.19	−54.19
Net Profit	1,124	1,058	876	1,350	1,374	1,981	2,956	1,821	1,596	2,186	2,565	2,920
EPS (Rs)	42.55	40.04	33.12	51.10	52.00	74.94	111.78	68.89	60.43	82.79	97.04	110.48
Dividend payout %	24.0%	25.0%	30.0%	31.0%	31.1%	27.0%	27.0%	44.1%	50.0%	36.0%	31.0%	—

Divi's Laboratories balance sheet

₹ crore, at each year end.

Divi's Laboratories Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	27.09	53.17	53.17	53.21	53.22	53.19	53.20	53.23	53.17	53.23	53.19	53.24
Reserves	3,469	4,246	5,306	5,873	6,908	7,266	9,246	11,686	12,716	13,539	14,927	16,716
Borrowings	26.95	41.90	35.91	62.86	106	38.90	4.99	3.99	2.99	2.99	3.99	6.98
Other Liabilities	886	559	763	800	972	1,180	1,478	1,636	1,661	1,877	1,939	3,250
Total Liabilities	4,408	4,901	6,158	6,789	8,039	8,536	10,782	13,380	14,435	15,472	16,923	20,026
Fixed Assets	1,309	1,439	1,557	1,994	2,088	2,779	3,704	4,325	4,718	4,733	5,435	6,523
CWIP	218	265	445	120	493	922	712	470	212	779	1,023	2,115
Investments	732	803	1,629	1,889	1,945	970	0.00	71.98	76.94	82.01	64.95	68.96
Other Assets	2,149	2,395	2,526	2,786	3,515	3,865	6,366	8,512	9,427	9,878	10,400	11,319
Inventories	1,162	1,207	1,319	1,350	1,771	1,861	2,142	2,826	2,996	3,182	3,230	3,951
Trade receivables	744	884	904	1,017	1,167	1,418	1,681	2,431	1,799	2,161	2,739	2,993
Cash & equivalents	65.09	73.08	79.14	112	115	123	2,159	2,823	4,217	3,985	3,717	3,418
Total Assets	4,408	4,901	6,158	6,789	8,039	8,536	10,782	13,380	14,435	15,472	16,923	20,026

Divi's Laboratories cash flow

₹ crore, for each year.

Divi's Laboratories Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	823	1,034	1,147	774	951	1,212	1,941	1,904	2,452	1,257	1,646	2,728
Cash from investing activity	−521	−406	−1,140	−478	−684	−83.01	74.99	−2,196	−2,706	−269	−804	−2,218
Cash from financing activity	−302	−629	1.99	−313	−245	−1,088	−34.85	−530	−794	−796	−796	−801
Net cash flow	3.01	0.00	13.04	−17.05	23.06	41.12	1,993	−818	−1,049	194	50.15	−286
Capex	308	396	377	274	734	1,184	911	714	474	1,003	1,440	2,522
Free cash flow	518	640	772	500	220	32.88	1,034	1,196	1,980	257	214	220
CFO / OP %	87.9%	90.9%	99.9%	81.9%	76.9%	91.0%	89.9%	65.9%	123.9%	73.9%	83.0%	105.0%

Divi's Laboratories ratios

Working-capital days and returns, by year.

Divi's Laboratories Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	87	85	81	95	86	96	88	99	84	100	106	103
Inventory days	351	294	308	315	348	317	330	342	353	365	312	347
Days payable	69	57	105	97	97	101	118	97	90	95	89	107
Cash conversion cycle	367	321	283	312	335	311	299	343	346	369	329	342
Working capital days	140	158	147	176	169	180	152	177	188	206	192	195
ROCE %	33.1%	36.0%	29.1%	22.1%	29.0%	25.1%	32.0%	35.1%	19.1%	16.1%	20.1%	22.1%

Divi's Laboratories: frequently asked questions

What are the latest quarterly results of Divi's Laboratories?

For the Jun 2026 quarter, Divi's Laboratories reported sales of ₹3,069 Cr, up 27.8% year on year and net profit of ₹900 Cr, up 65.4% year on year. The operating margin was 41.0%.

What is the annual revenue of Divi's Laboratories?

Divi's Laboratories' sales for the year to Mar 2026 were ₹10,535 Cr; over the last twelve months they were ₹11,197 Cr.

What is the net profit of Divi's Laboratories?

Net profit for the year to Mar 2026 was ₹2,565 Cr, and ₹2,920 Cr over the last twelve months. Earnings per share over the same trailing period were ₹110.48.

How much debt does Divi's Laboratories have?

Divi's Laboratories reported borrowings of ₹6.98 Cr at Mar 2026, against cash and equivalents of ₹3,418 Cr.

What is the free cash flow of Divi's Laboratories?

Cash from operations was ₹2,728 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹220 Cr.

Loading…